Cognition Therapeutics Advances Zervimesine Toward Phase 2b Trial

Cognition Therapeutics ( (CGTX) ) just unveiled an announcement.

On January 21, 2026, Cognition Therapeutics held a Type C meeting with the U.S. Food and Drug Administration to review plans for a proposed Phase 2b trial of its investigational drug zervimesine in patients with mild-to-moderate dementia with Lewy bodies, a neurodegenerative disease that currently has no FDA-approved therapies, and disclosed the completion of this meeting in a January 27, 2026 press release. The company’s engagement with regulators on clinically meaningful endpoints underscores its efforts to advance zervimesine—previously shown to be generally well tolerated and designed to counter toxic protein build-up in the brain—into later-stage studies, a step that could be strategically important for its clinical pipeline and for stakeholders watching progress in treatments for dementia with Lewy bodies and related CNS disorders.

The most recent analyst rating on (CGTX) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Cognition Therapeutics stock, see the CGTX Stock Forecast page.

Spark’s Take on CGTX Stock

According to Spark, TipRanks’ AI Analyst, CGTX is a Neutral.

The score is held down primarily by very weak financial performance (minimal revenue, sizable losses, and heavy cash burn), which raises ongoing funding/dilution risk despite low balance-sheet leverage. Technicals are also weak with a below-moving-average trend and negative MACD, while valuation provides limited support due to negative earnings and no dividend yield data.

To see Spark’s full report on CGTX stock, click here.

More about Cognition Therapeutics

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative small-molecule therapeutics for age-related degenerative disorders of the central nervous system. Its lead candidate, zervimesine (CT1812), an oral once-daily pill targeting the sigma-2 receptor, is being developed for conditions including dementia with Lewy bodies, Alzheimer’s disease and geographic atrophy secondary to dry age-related macular degeneration, with ongoing Phase 2 programs supported in part by substantial grant funding from the U.S. National Institute on Aging.

Average Trading Volume: 973,654

Technical Sentiment Signal: Buy

Current Market Cap: $121.8M

For detailed information about CGTX stock, go to TipRanks’ Stock Analysis page.